China National Accord Medicines (SZSE:200028) Moat Score: 0/10 (As of Sep. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:200028 China National Accord Medicines Corp Ltd SZSE:200028
82 GF Score
Price HK$12.01
GF Value HK$13.65
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is China National Accord Medicines Moat Score?

China National Accord Medicines has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

China National Accord Medicines has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes China National Accord Medicines might have No Moat - No discernible moat.

China National Accord Medicines  (SZSE:200028) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

China National Accord Medicines Moat Score Related Terms

SZSE:200028
82GF Score
China National Accord Medicines Corp Ltd SZSE:200028
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China National Accord Medicines (SZSE:200028) Overvalued in 2026?

Based on GuruFocus' analysis, China National Accord Medicines stock appears to be undervalued. The current stock price of HK$12.01 is trading 12% below its estimated GF Value™ of HK$13.65. GuruFocus considers China National Accord Medicines to be Modestly Undervalued.

Key valuation signals for SZSE:200028:

  • Moat Score: 0
  • GF Value™: HK$13.65 vs. price of HK$12.01 (12% below fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the SZSE:200028 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China National Accord Medicines Business Description

Other Exchanges 000028:China
Address No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.
82GF Score

Get the complete analysis for SZSE:200028

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$12.01
Price
HK$13.65
GF Value